Global Candidiasis Drugs Market Outlook Report, 2019-2023 - Advances in Diagnosis of Antifungal Resistant Pathogens to Drive Market Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 6, 2019--The “Global Candidiasis Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The candidiasis drugs market will register a CAGR of almost 4% by 2023.
Advances in diagnosis of antifungal resistant pathogens to drive market growth
Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs. For instance, Candida auris, an emerging antifungal-resistant yeast, is frequently resistant to multiple antifungal drugs that were used to treat Candida infections.
Moreover, it can cause serious bloodstream infections in hospitalized patients. Hence, advanced technologies are required for the diagnosis of such fungal diseases caused by antifungal-resistant pathogens.
Rising awareness about candidiasis
The signs and symptoms of candidiasis are very broad, and they also depend on the type of candidiasis infection. They sometimes resemble the symptoms of other diseases caused by bacteria. Hence, confirmatory diagnosis methods are required to confirm the disease after assessing the initial symptoms.
Early detection can aid in treating them more effectively. Therefore, to create awareness about the disease and treatment options and avoid delay in diagnosis, the CDC is providing information about candidiasis, and its causes, risk factors, transmission, diagnosis, and treatment in the US.
Side effects of available drugs
Although several off-label medications are available for the symptomatic treatment of candidiasis, the side effects associated with them are decreasing their preference. For instance, polyene antifungal medicine, nystatin causes mouth irritation, diarrhea, nausea, vomiting, stomach upset, rashes, hives, and skin irritation.
Although azole medications such as fluconazole, voriconazole, and miconazole are usually well tolerated, they cause side effects such as a headache, nausea, abdominal pain, diarrhea, vomiting, dyspepsia, liver damages, and rashes.
The market appears to be fragmented, and with the presence of several companies including Merck and Pfizer, the competitive environment is quite intense.
Key PlayersAstellas Pharma Bayer Fresenius Merck Pfizer
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 06: MARKET SEGMENTATION BY TYPEComparison by type Azoles - Market size and forecast 2018-2023 Echinocandins - Market size and forecast 2018-2023 Other drugs - Market size and forecast 2018-2023 Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPEGeographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 09: DRIVERS AND CHALLENGES
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPEOverview Landscape disruption Competitive scenario
PART 12: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Astellas Pharma Bayer Fresenius Merck Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/btts6l/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190206005534/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/06/2019 11:47 AM/DISC: 02/06/2019 11:47 AM